IMPORTANT UPDATES

No Bleeding Required: Detecting Anemia Using a Smartphone


ATLANTA (Dec. 4, 2018) – Biomedical engineers have developed a smartphone app with the aim of noninvasive detection of anemia. Instead of a blood test, the app uses photos of someone’s fingernails taken on a smartphone to determine whether the level of hemoglobin in their blood seems low.

The results are scheduled for publication in Nature Communications.

“All other ‘point-of-care’ anemia detection tools require external equipment, and represent trade-offs between invasiveness, cost, and accuracy,” said Wilbur Lam, MD, PhD, Private Investigator on the project. “This is a standalone app that can look at hemoglobin levels without the need to draw blood.”

Dr. Lam is a Pediatric Hematologist/Oncologist and Bioengineer at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, Associate Professor of Pediatrics at Emory University School of Medicine and a faculty member in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Institute of Technology.

The app is part of the PhD work of former biomedical engineering graduate student Rob Mannino, PhD, who was motivated to conduct the research by his own experience living with beta-thalassemia, an inherited blood disorder caused by a mutation in the beta-globin gene.

“Treatment for my disease requires monthly blood transfusions,” Dr. Mannino said. “My doctors would test my hemoglobin levels more if they could, but it’s a hassle for me to get to the hospital in between transfusions to receive this blood test. Instead, my doctors currently have to just estimate when I’m going to need a transfusion, based on my hemoglobin level trends.”

“This whole project couldn’t have been done by anyone but Rob,” Dr. Lam said. “He took pictures of himself before and after transfusions as his hemoglobin levels were changing, which enabled him to constantly refine and tweak his technology on himself in a very efficient manner. So essentially, he was his own perfect initial test subject with each iteration of the app.”

Drs. Mannino and Lam said that their app could facilitate self-management by patients with chronic anemia, allowing them to monitor their disease and to identify the times when they need to adjust their therapies or receive transfusions, possibly reducing side effects or complications of having transfusions too early or too late.

The researchers said that the app should be used for screening, not clinical diagnosis. The technology could be used by anyone at any time, and could be especially appropriate for pregnant women, women with abnormal menstrual bleeding or runners and athletes. Its simplicity means it could be useful in developing countries. Clinical diagnostic tools have strict accuracy requirements, but Drs. Mannino and Lam think that with additional research, they can eventually achieve the accuracy needed to replace blood-based anemia testing for clinical diagnosis.

Anemia is a blood condition that affects 2 billion people worldwide and can lead to fatigue, paleness and cardiac distress if left untreated. The current gold standard for anemia diagnosis is known as a complete blood count (CBC).

The researchers studied fingernail photos and correlated the color of the fingernail beds with hemoglobin levels measured by CBC in 337 people: some healthy and others with a variety of anemia diagnoses. The algorithm for converting fingernail color to blood hemoglobin level was developed with 237 of these subjects and then tested on 100.

The researchers were able to show that a single smartphone image, without personalized calibration, can measure hemoglobin level with an accuracy of 2.4 grams/deciliter with a sensitivity of up to 97%. Personalized calibration, tested on four patients over the course of several weeks, can improve the accuracy to 0.92 grams/deciliter, a degree of accuracy on par with point-of-care blood-based hemoglobin tests. Normal values are 13.5 to 17.5 grams/deciliter for males and 12.0 to 15.5 grams/deciliter for females.

In the app, the use of fingernail beds, which do not contain melanin, means the test can be valid for people with a variety of skin tones. The accuracy is consistent for dark or light skin tones, said Dr. Mannino. The app uses image metadata to correct for background brightness and can be adapted to phones from multiple manufacturers.

Drs. Mannino and Lam said they are working with a variety of doctors at Children’s and Emory University—geriatric, internal medicine, neonatologists, transfusion medicine, global health—to obtain additional data and better calibrate their system.

“This is just a snapshot of the accuracy right now,” Dr. Lam said. “The algorithm gets smarter with every patient enrolled.”

The research was supported by the National Science Foundation (Graduate Research Fellowship DGE-1650044 and Southeastern Nanotechnology Infrastructure Corridor 1542174), the 2017 Massachusetts General Hospital Primary Care Technology Prize, and National Institutes of Health (R21 EB025646).

The smartphone anemia app is projected to be available commercially for public download as soon as spring 2019.

A patent application has been filed for the anemia app, and Drs. Lam and Mannino have a financial interest in the success of this product.

About The Aflac Cancer and Blood Disorders Center of Children’s

The Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta is a national leader among childhood cancer, hematology, and blood and marrow transplant programs, serving children and young adults. Recognized as one of the top childhood cancer centers in the country by U.S. News & World Report, the Aflac Cancer and Blood Disorders Center cares for more than 500 newly diagnosed cancer patients and treats nearly 2,000 unique sickle cell disease patients each year. Our program offers patients access to more than 380 clinical trials, including 28 innovative Aflac Cancer and Blood Disorders Center investigator-initiated trials. Visit choa.org/cancer for more information.

* Required fields